HBV - FDA-approved Therapy




Tyzeka (telbivudine)

•Data From GLOBE Trial Confirm Efficacy of Telbivudine for Chronic Hepatitis B  11/03/06
•Idenix to Present Studies on Telbivudine for Chronic Hepatitis B  11/03/06


Hepsera (adefovir dipivoxil)

•Long-term Efficacy and Safety of Adefovir in HBeAg-positive Hepatitis B Patients  11/03/06
•Meta-analysis Across Adefovir Clinical Trials Demonstrates the Absence of Novel Adefovir-Associated Mutations and Confi rms the Role of the rtA181V and rtN236T Mutations in HBV Polymerase in Association with Virologic Failure
K Borroto-Esoda and others. Poster #976.
•In Vitro Susceptibility of HBV Polymerase Encoding Mutations Acquired During Adefovir Dipivoxil Therapy to Other Anti-HBV Agents
X Qi and others. Oral Presentation #171.

Baraclude (entecavir)

•Entecavir Produces Greater HBV DNA Suppression than Adefovir or Lamivudine in Treatment-naive HBeAg Positive Patients  11/10/06
•Long-Term Response to Entecavir and Emergence of Resistance Mutations  11/10/06











Google_______________


 

 

 

 

 

 

 

 

 

 

 

 

 

 


Conference
Main Page

Hepatitis C
FDA-Approved
Treatments

Monotherapies
Intron A
Roferon
Infergen
Pegasys
PEG-Intron

Combination
 Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin

Hepatitis B
FDA-Approved
Treatments

Baraclude
 Epivir-HBV
 Hepsera
 Intron A
 Pegasys
 Tyzeka